Giovanni Di Zenzo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/529483/publications.pdf

Version: 2024-02-01

70 papers

2,851 citations

201674 27 h-index 189892 50 g-index

70 all docs

70 docs citations

times ranked

70

2505 citing authors

#	Article	IF	CITATIONS
1	Pemphigus Vulgaris: Present and Future Therapeutic Strategies. Dermatology Practical and Conceptual, 2022, 12, e2022037.	0.9	9
2	Bullous Pemphigoid Associated With COVID-19 Vaccines: An Italian Multicentre Study. Frontiers in Medicine, 2022, 9, 841506.	2.6	30
3	Gliptin-associated bullous pemphigoid shows peculiar features of anti-BP180 and -BP230 humoral response: Results of a multicenter study. Journal of the American Academy of Dermatology, 2022, 87, 56-63.	1.2	10
4	IgE autoantibodies in serum and skin of nonâ€bullous and bullous pemphigoid patients. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 973-980.	2.4	22
5	Paraneoplastic autoimmune multiorgan syndrome. Italian Journal of Dermatology and Venereology, 2021, 156, .	0.2	6
6	A Review of Acquired Autoimmune Blistering Diseases in Inherited Epidermolysis Bullosa: Implications for the Future of Gene Therapy. Antibodies, 2021, 10, 19.	2.5	6
7	May Bacterial Infections Trigger Bullous Pemphigoid? Case Report and Review of Literature. Microorganisms, 2021, 9, 1235.	3.6	3
8	European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part I. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1750-1764.	2.4	72
9	European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part II. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1926-1948.	2.4	86
10	Blistering lesions associated with Waldenström macroglobulinemia: New insights into pathogenesis. Dermatologic Therapy, 2021, 34, e15072.	1.7	1
11	Bullous pemphigoid in diabetic patients treated by gliptins: the other side of the coin. Journal of Translational Medicine, 2021, 19, 520.	4.4	15
12	Evaluation of cutaneous, oral and intestinal microbiota in patients affected by pemphigus and bullous pemphigoid: A pilot study. Experimental and Molecular Pathology, 2020, 112, 104331.	2.1	16
13	Development of bullous pemphigoid in junctional epidermolysis bullosa. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e146-e148.	2.4	4
14	Bullous Pemphigoid: Trigger and Predisposing Factors. Biomolecules, 2020, 10, 1432.	4.0	81
15	Multicenter prospective study on multivariant diagnostics of autoimmune bullous dermatoses using the BIOCHIP technology. Journal of the American Academy of Dermatology, 2020, 83, 1315-1322.	1.2	28
16	New Insights Into the Pathogenesis of Bullous Pemphigoid: 2019 Update. Frontiers in Immunology, 2019, 10, 1506.	4.8	99
17	Interâ€rater reliability of the BIOCHIP indirect immunofluorescence dermatology mosaic in bullous pemphigoid and pemphigus patients. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 2327-2333.	2.4	9
18	Identification of a Novel Non-desmoglein Autoantigen in Pemphigus Vulgaris. Frontiers in Immunology, 2019, 10, 1391.	4.8	4

#	Article	IF	CITATIONS
19	Commentary on †Changing prevalence of diabetes mellitus in bullous pemphigoid: it is the dipeptidyl peptidaseâ€4 inhibitors'. Journal of the European Academy of Dermatology and Venereology, 2018, 32, e439-e440.	2.4	8
20	Lack of K140 immunoreactivity in junctional epidermolysis bullosa skin and keratinocytes associates with misfolded laminin epidermal growth factor-like motif 2 of the \hat{I}^2 3 short arm. British Journal of Dermatology, 2018, 178, 1416-1422.	1.5	7
21	Increased prevalence of diabetes mellitus in bullous pemphigoid patients during the last decade. Journal of the European Academy of Dermatology and Venereology, 2018, 32, e153-e154.	2.4	17
22	Detection and characterization of IgG, IgE, and IgA autoantibodies in patients with bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors. Journal of the American Academy of Dermatology, 2018, 78, 592-595.	1.2	39
23	Immunoglobulin E and bullous pemphigoid. European Journal of Dermatology, 2018, 28, 440-448.	0.6	34
24	Epidermolysis Bullosa (EB) Acquisita in an Adult Patient with Previously Unrecognized Mild Dystrophic EB and Biallelic COL7A1 Mutations. Acta Dermato-Venereologica, 2018, 98, 411-415.	1.3	11
25	Humoral Epitope Spreading in Autoimmune Bullous Diseases. Frontiers in Immunology, 2018, 9, 779.	4.8	77
26	Bullous pemphigoid with hyperkeratosis and palmoplantar keratoderma: Three cases. Journal of Dermatology, 2018, 45, 1135-1140.	1.2	3
27	Childhood epidermolysis bullosa acquisita during squaric acid dibutyl ester immunotherapy for alopecia areata. British Journal of Dermatology, 2017, 176, 491-494.	1.5	11
28	IgA tracheobronchial deposits underlie respiratory compromise in neonatal linear IgA bullous dermatosis. Journal of the European Academy of Dermatology and Venereology, 2017, 31, e333-e335.	2.4	5
29	Meeting Report of the Pathogenesis of Pemphigus and Pemphigoid Meeting in Munich, September 2016. Journal of Investigative Dermatology, 2017, 137, 1199-1203.	0.7	34
30	Prospective studies on the routine use of a novel multivariant enzyme-linked immunosorbent assay for the diagnosis of autoimmune bullous diseases. Journal of the American Academy of Dermatology, 2017, 76, 889-894.e5.	1.2	46
31	Determining the Incidence of <i>Pneumocystis</i> Pneumonia in Patients With Autoimmune Blistering Diseases Not Receiving Routine Prophylaxis. JAMA Dermatology, 2017, 153, 1137.	4.1	43
32	Serological diagnostics in the detection of IgG autoantibodies against human collagen VII in epidermolysis bullosa acquisita: a multicentre analysis. British Journal of Dermatology, 2017, 177, 1683-1692.	1.5	30
33	The pathogenesis of pemphigus: Controversy vs complexity. Experimental Dermatology, 2017, 26, 1271-1273.	2.9	7
34	Paraneoplastic Autoimmune Multi-organ Syndrome: Association with Retroperitoneal Kaposi's Sarcoma. Acta Dermato-Venereologica, 2016, 96, 261-262.	1.3	4
35	Pemphigoid Gestationis Complicating an Egg Donation Pregnancy. Acta Dermato-Venereologica, 2016, 96, 695-696.	1.3	3
36	Paraneoplastic Epidermolysis Bullosa Acquisita Associated with Thyroid Carcinoma. Acta Dermato-Venereologica, 2016, 96, 414-415.	1.3	3

#	Article	lF	CITATIONS
37	New versatile monoclonal antibodies against type <scp>XVII</scp> collagen endodomain for diagnosis and subtyping <i><scp>COL</scp>17A1</i> êessociated junctional epidermolysis bullosa. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1426-1427.	2.4	1
38	Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science, 2016, 353, 179-184.	12.6	468
39	Immune response in pemphigus and beyond: progresses and emerging concepts. Seminars in Immunopathology, 2016, 38, 57-74.	6.1	68
40	A compound synonymous mutation c.474G> A with p.Arg578X mutation in <i><scp>SPINK</scp>5</i> causes splicing disorder and mild phenotype in Netherton syndrome. Experimental Dermatology, 2016, 25, 568-570.	2.9	6
41	The pathogenic activity of anti-desmoglein autoantibodies parallels disease severity in rituximab-treated patients with pemphigus vulgaris. European Journal of Dermatology, 2015, 25, 578-585.	0.6	7
42	Clonal Analysis of B-Cell Response in Pemphigus Course: Toward More Effective Therapies. Journal of Investigative Dermatology, 2015, 135, 651-654.	0.7	3
43	Autoantibody Profile of a Cohort of 78 Italian Patients with Mucous Membrane Pemphigoid: Correlation Between Reactivity Profile and Clinical Involvement. Acta Dermato-Venereologica, 2014, 96, 768-73.	1.3	21
44	Oral lichenoid tissue reactions: diagnosis and classification. Expert Review of Molecular Diagnostics, 2014, 14, 169-184.	3.1	63
45	Sensitivity of different assays for the serological diagnosis of epidermolysis bullosa acquisita: analysis of a cohort of 24 Italian patients. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 483-490.	2.4	12
46	A truncating mutation in the laminin-332α chain highlights the role of the LG45 proteolytic domain in regulating keratinocyte adhesion and migration. British Journal of Dermatology, 2014, 170, 1056-1064.	1.5	11
47	Monozygotic twins discordant for recessive dystrophic epidermolysis bullosa phenotype highlight the role of TGF-β signalling in modifying disease severity. Human Molecular Genetics, 2014, 23, 3907-3922.	2.9	88
48	Urban legend series: mucous membrane pemphigoid. Oral Diseases, 2014, 20, 35-54.	3.0	38
49	Detection of IgG and IgE reactivity to BP180 using the ISAC®microarray system. British Journal of Dermatology, 2013, 168, 1205-1214.	1.5	24
50	Induction of senescence pathways in Kindler syndrome primary keratinocytes. British Journal of Dermatology, 2013, 168, 1019-1026.	1.5	18
51	Are clinical phenotype and autoantibody profile always concordant in pemphigus? A study in a cohort of pemphigus patients. European Journal of Dermatology, 2013, 23, 40-48.	0.6	20
52	Endemic Pemphigus Foliaceus: Towards Understanding Autoimmune Mechanisms of Disease Development. Journal of Investigative Dermatology, 2012, 132, 2499-2502.	0.7	11
53	Bullous pemphigoid: From the clinic to the bench. Clinics in Dermatology, 2012, 30, 3-16.	1.6	123
54	Prevalence of collagen VII-specific autoantibodies in patients with autoimmune and inflammatory diseases. BMC Immunology, 2012, 13, 16.	2.2	30

#	Article	IF	CITATIONS
55	Pemphigus autoantibodies generated through somatic mutations target the desmoglein-3 cis-interface. Journal of Clinical Investigation, 2012, 122, 3781-3790.	8.2	142
56	Demonstration of Epitope-Spreading Phenomena in Bullous Pemphigoid: Results of a Prospective Multicenter Study. Journal of Investigative Dermatology, 2011, 131, 2271-2280.	0.7	132
57	Sensitivity of Immunofluorescence Studies vs Enzyme-Linked Immunosorbent Assay for Diagnosis of Bullous Pemphigoid. Archives of Dermatology, 2011, 147, 1454.	1.4	3
58	Anti-desmoplakin antibodies in erythema multiforme and Stevens-Johnson syndrome sera: pathogenic or epiphenomenon?. European Journal of Dermatology, 2011, 21, 32-36.	0.6	25
59	Bullous Pemphigoid: Clinical Features, Diagnostic Markers, and Immunopathogenic Mechanisms. , 2011, , 65-95.		1
60	Paraneoplastic Pemphigus Presenting as Mild Cutaneous Features of Pemphigus Foliaceus and Lichenoid Stomatitis with Antidesmoglein 1 Antibodies. Dermatology Research and Practice, 2010, 2010, 1-5.	0.8	8
61	Sequential Intramolecular Epitope Spreading of Humoral Responses to Human BPAG2 in a Transgenic Model. Journal of Investigative Dermatology, 2010, 130, 1040-1047.	0.7	28
62	Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid. Clinical Immunology, 2008, 128, 415-426.	3.2	173
63	Minocycline in combination with mycophenolate mofetil in oral mucous membrane pemphigoid. European Journal of Dermatology, 2008, 18, 198-200.	0.6	7
64	Bullous Pemphigoid: Physiopathology, Clinical Features and Management. Advances in Dermatology, 2007, 23, 257-288.	2.0	101
65	The Intracellular and Extracellular Domains of BP180 Antigen Comprise Novel Epitopes Targeted by Pemphigoid Gestationis Autoantibodies. Journal of Investigative Dermatology, 2007, 127, 864-873.	0.7	57
66	Oral pemphigoid autoantibodies preferentially target BP180 ectodomain. Clinical Immunology, 2007, 122, 207-213.	3.2	51
67	Development of a novel ELISA system for detection of anti-BP180 IgG and characterization of autoantibody profile in bullous pemphigoid patients. British Journal of Dermatology, 2004, 151, 1004-1010.	1.5	75
68	Mammalian cell transduction and internalization properties of \hat{l} » phages displaying the full-length adenoviral penton base or its central domain. Journal of Molecular Medicine, 2004, 82, 467-476.	3.9	38
69	Characterization of the Anti-BP180 Autoantibody Reactivity Profile and Epitope Mapping in Bullous Pemphigoid Patients11Tables 1, 2, 3 and 5 can be found at http://www.blackwellpublishing.com/products/journals/suppmat/jid/jid22126/jid22126sm.htm. Journal of Investigative Dermatology, 2004, 122, 103-110.	0.7	89
70	Contribution of the different modules in the utrophin carboxy-terminal region to the formation and regulation of the DAP complex. FEBS Letters, 2000, 471, 229-234.	2.8	26